Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]-

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]-

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- Structure
L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- structure
CAS No.
1233589-81-5
Chemical Name:
L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]-
Synonyms
CRX-601;GSK1795091;L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]-
CBNumber:
CB58131732
Molecular Formula:
C81H157N2O16P
Molecular Weight:
1446.12
MDL Number:
MOL File:
1233589-81-5.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-04-24 14:58:55
Product description Number Pack Size Price
GSK1795091 94.48% CS-0092310 1mg $932
GSK1795091 94.48% CS-0092310 5mg $2329
GSK1795091 94.48% CS-0092310 10mg $3727
GSK1795091 94.48% CS-0092310 25mg $7041
GSK1795091 94.48% CS-0092310 50mg $10562
Request For Quotation

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- Properties

Density 1.05±0.1 g/cm3(Predicted)
pka 1.83±0.10(Predicted)
FDA UNII 5D8VHL5WH5

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0092310 GSK1795091 94.48% 1233589-81-5 1mg $932 2026-06-04 Buy
ChemScene CS-0092310 GSK1795091 94.48% 1233589-81-5 5mg $2329 2026-06-04 Buy
ChemScene CS-0092310 GSK1795091 94.48% 1233589-81-5 10mg $3727 2026-06-04 Buy
ChemScene CS-0092310 GSK1795091 94.48% 1233589-81-5 25mg $7041 2026-06-04 Buy
ChemScene CS-0092310 GSK1795091 94.48% 1233589-81-5 50mg $10562 2026-06-04 Buy
Product number Packaging Price Buy
CS-0092310 1mg $932 Buy
CS-0092310 5mg $2329 Buy
CS-0092310 10mg $3727 Buy
CS-0092310 25mg $7041 Buy
CS-0092310 50mg $10562 Buy

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- Chemical Properties,Uses,Production

Uses

GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice[1][2][3].

in vivo

GSK1795091 (CRX-601) ( 0.1 μg /mouse, intranasal administration) as an adjuvant combined with detergent split-influenza antigen (H3N2) induces strong both mucosal and systemic immune responses in mice[2].
GSK1795091 (25 μg/mouse; iv; once weekly for 3 doses) inhibits tumor growth and results in long term survival in tumor model in mice[3].

Animal Model:Female BALB/c mice primed with H3N2[1]
Dosage:0.1 μg /mouse
Administration:Intranasal administration
Result:As an adjuvant combined with detergent split-influenza antigen (H3N2) generated strong local and systemic immunity against co-administered influenza antigens while exhibiting high efficacy against two heterotypic influenza challenges.
Mice receiving adjuvanted vaccines had significantly higher IgA titers than non-adjuvanted (vehicle) controls in an adjuvant dose-dependent manner.
Adjuvanted vaccines promoted antigen-specific IgG and IgA antibody responses and the generation of polyfunctional antigen-specific Th17 cells.

References

[1] Hug BA, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clin Ther. 2020;42(8):1519-1534.e33. DOI:10.1016/j.clinthera.2020.05.022
[2] Maroof A, et.al. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014 Jan;10(1):e1003875. DOI:10.1371/journal.ppat.1003875
[3] Cebada J, et al. OX40 agonists for cancer treatment: a patent review. Expert Opin Ther Pat. 2021 Jan;31(1):81-90. DOI:10.1080/13543776.2021.1825688

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- Preparation Products And Raw materials

Raw materials

Preparation Products

L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- Suppliers

Global( 1)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc. 15002134094 marketing@targetmol.cn China 29855 58
Supplier Advantage
TargetMol Chemicals Inc. 58
L-Serine, N-[(3R)-3-(decyloxy)-1-oxotetradecyl]-O-[3-O-[(3R)-3-(decyloxy)-1-oxotetradecyl]-2-[[(3R)-3-(decyloxy)-1-oxotetradecyl]amino]-2-deoxy-4-O-phosphono-β-D-glucopyranosyl]- CRX-601 GSK1795091 1233589-81-5 C81H157N2O16P